Kanghong Pharmaceutical

Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd. (hereinafter referred to as "Kanghong Pharmaceutical", stock code: 002773) is a pharmaceutical group dedicated to the research, development, production, sales, and after-sales service of biological products, traditional Chinese medicines, and chemical drugs, including 7 subsidiaries such as Kanghong Biologics, Kanghong Pharmaceutical, and Jishengtang. Kanghong Pharmaceutical has always adhered to the core development strategy of professionalism, innovation, and internationalization, possessing a corporate technology center, a postdoctoral research workstation, and a key laboratory of Sichuan Province, and has established multiple innovation platforms related to biological products, chemical drugs, and traditional Chinese medicines. Currently, Kanghong Pharmaceutical lays out its products based on the clinical needs of core therapeutic areas, with main products covering core therapeutic areas including ophthalmology, central nervous system, digestive system, and others. Currently, it holds more than 120 invention patents (over 40 foreign patents) and has undertaken one National Key Basic Research and Development Program (973 Plan), three National High-Tech Research and Development Programs (863 Plan), three National "Major New Drug Creation" Science and Technology Major Projects and other special projects, as well as over 30 science and technology key projects in Sichuan Province and Chengdu.
Kanghong Pharmaceutical adheres to the development strategy of combining professionalism and innovation, focusing on the research and development of innovative products, achieving a sustainable development strategy of "producing one generation, reserving one generation, and developing one generation." Currently, Kanghong Pharmaceutical has 12 main products in production and 10 main products under research. Among them, Kanghong's independently developed China-original Class 1 biological new drug Conbercept ophthalmic injection (trade name: Lumitin) obtained the new drug certificate and drug registration approval from the National Food and Drug Administration in November 2013, and was launched in March 2014, filling the market gap for domestic treatment of macular degeneration and breaking the monopoly of imported drugs in this field in the Chinese market, providing many Chinese patients facing blindness with better and more economical treatment opportunities. Facing the fierce competition pattern of innovative drugs, Kanghong actively explores professional academic dissemination of this product at home and abroad, builds professional and innovative academic competitiveness, shapes an international national brand, and lays a good foundation for Chinese drugs to enter the international market and for the world to know Kanghong and accept Lumitin.
Since its establishment, Kanghong Pharmaceutical has received care and guidance from governments at all levels and widespread attention from all sectors of society: in 2012, it was listed by the Ministry of Science and Technology, the State-owned Assets Supervision and Administration Commission of the State Council, and the All-China Federation of Trade Unions as one of the fifth batch of national "Innovative Pilot Enterprises"; in 2013, it was rated as an "Excellent Private Enterprise" by the Sichuan Provincial People's Government; in 2014, it was rated as one of the "Top 100 Chinese Pharmaceutical Manufacturing Enterprises" by the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce.
Kanghong Pharmaceutical will, as always, uphold the corporate purpose of "prosperous era and helping all beings," adhere to the professional and innovative development path, continue to develop high-quality, high-tech pharmaceutical products, serve public health, promote industrial progress, and repay social care.
Company homepage: